JP2003522737A5 - - Google Patents

Download PDF

Info

Publication number
JP2003522737A5
JP2003522737A5 JP2001536585A JP2001536585A JP2003522737A5 JP 2003522737 A5 JP2003522737 A5 JP 2003522737A5 JP 2001536585 A JP2001536585 A JP 2001536585A JP 2001536585 A JP2001536585 A JP 2001536585A JP 2003522737 A5 JP2003522737 A5 JP 2003522737A5
Authority
JP
Japan
Prior art keywords
animal
compound
level
test compound
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001536585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522737A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/030310 external-priority patent/WO2001035106A2/en
Publication of JP2003522737A publication Critical patent/JP2003522737A/ja
Publication of JP2003522737A5 publication Critical patent/JP2003522737A5/ja
Pending legal-status Critical Current

Links

JP2001536585A 1999-11-05 2000-11-03 アミロイド阻害化合物を同定しそして使用するための方法 Pending JP2003522737A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16381999P 1999-11-05 1999-11-05
US60/163,819 1999-11-05
PCT/US2000/030310 WO2001035106A2 (en) 1999-11-05 2000-11-03 Methods for identifying and using amyloid-inhibitory compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007285586A Division JP2008058329A (ja) 1999-11-05 2007-11-01 アミロイド阻害化合物を同定しそして使用するための方法

Publications (2)

Publication Number Publication Date
JP2003522737A JP2003522737A (ja) 2003-07-29
JP2003522737A5 true JP2003522737A5 (https=) 2007-12-27

Family

ID=22591720

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001536585A Pending JP2003522737A (ja) 1999-11-05 2000-11-03 アミロイド阻害化合物を同定しそして使用するための方法
JP2007285586A Pending JP2008058329A (ja) 1999-11-05 2007-11-01 アミロイド阻害化合物を同定しそして使用するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007285586A Pending JP2008058329A (ja) 1999-11-05 2007-11-01 アミロイド阻害化合物を同定しそして使用するための方法

Country Status (10)

Country Link
US (1) US20080085244A1 (https=)
EP (1) EP1272853A2 (https=)
JP (2) JP2003522737A (https=)
AR (1) AR027878A1 (https=)
AU (2) AU2005200176B2 (https=)
CA (1) CA2390161A1 (https=)
MX (1) MXPA02004480A (https=)
NZ (3) NZ518780A (https=)
TW (3) TW200834074A (https=)
WO (1) WO2001035106A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US20020173499A1 (en) * 2001-03-16 2002-11-21 Wyeth Estrogen replacement therapy
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
US8658627B2 (en) 2001-04-25 2014-02-25 The Regents Of The University Of California Pregnancy hormone combination for treatment of autoimmune diseases
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
JP2007284351A (ja) * 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP2698167A3 (en) * 2005-09-26 2014-03-05 The Regents of The University of California Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4311870C2 (de) * 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
JP3552272B2 (ja) * 1994-05-27 2004-08-11 帝国臓器製薬株式会社 免疫化学的簡易アッセイ方法および装置
WO1997046664A1 (en) * 1996-06-06 1997-12-11 University Of Washington Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
JPH1090261A (ja) * 1996-08-23 1998-04-10 Fuotoreru Patrick 性ステロイドホルモン測定用プレート、これを用いた測定キット及び測定法
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
AU7260398A (en) * 1997-04-28 1998-11-24 University Of British Columbia, The Method and composition for modulating amyloidosis
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein

Similar Documents

Publication Publication Date Title
Yadid et al. Elucidation of the neurobiology of depression: insights from a novel genetic animal model
Simpkins et al. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat
Josefsson et al. Anti-inflammatory properties of estrogen: I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils
Ahrendt et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel
Sarkar Mifepristone: bioavailability, pharmacokinetics and use-effectiveness
Fiore et al. Treatment with the neurosteroid dehydroepiandrosterone promotes recovery of motor behavior after moderate contusive spinal cord injury in the mouse
Akbari et al. Increased tyrosine hydroxylase immunoreactivity in the rat cortex following prenatal cocaine exposure
Rosario et al. Progestins inhibit the neuroprotective effects of estrogen in rat hippocampus
JP2003522737A5 (https=)
DE60112301T2 (de) Verwendung von (deaminohydroxy)toremifen zur behandlung von vaginaler trockenheit oder sexuellen störungen während oder nach der menopause
DE102009007771A1 (de) Bukkales Applikationssystem, 17α-Estradiol enthaltend
EP1929291A2 (en) Estriol therapy for autoimmune and neurodegenerataive diseases and disorders
KR20150133182A (ko) 다발성 경화증의 치료를 위한 PPARγ 작용제
Baciewicz Oral contraceptive drug interactions
Frye et al. The neurosteroid, 3α-androstanediol, prevents inhibitory avoidance deficits and pyknotic cells in the granule layer of the dentate gyrus induced by adrenalectomy in rats
Seyedreza et al. Role of testosterone in memory impairment of Alzheimer disease induced by Streptozotocin in male rats
WO2007038435A2 (en) Estriol therapy for autoimmune and neurodegenerative diseases and disorders
Samuels et al. Pup-killing behavior in mice: Suppression by early androgen exposure
Pall et al. Deterioration of Wilson's disease following the start of penicillamine therapy
Duckers et al. The neurotrophic analogue of ACTH (4–9), Org 2766, protects against experimental allergic neuritis
AU2020358203A1 (en) Urination disorder-improving agent
Hoffman et al. Relevance of ovarian signaling for the early behavioral transition from estrus to pregnancy in the female rabbit
EP1468690A1 (en) Use of estrogens for the treatment of infertility in male mammals
JP2001505574A (ja) １７α−ジヒドロエキレニンを使用した神経退化および認識機能障害の予防方法
Waragai et al. Efficacy of TRH-T for spinocerebellar degeneration--the relation between clinical features and effect of TRH therapy